Steve Doberstein joined Nektar Therapeutics in January 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of the company’s drug discovery research.
Dr. Doberstein has over 17 years of experience in biotechnology research and development, and prior to joining Nektar Therapeutics was Vice President of Research at XOMA (NASDAQ:XOMA) where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and
Dr. Doberstein also served as Vice President, Research at Five Prime Therapeutics (NASDAQ:FPRX), a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group.
While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to working with Five Prime, Dr. Doberstein was Vice President, Research at Xencor (NASDAQ:XNCR), an antibody and protein engineering and development company. At Xencor, he was instrumental in advancing its protein platform technologies and preclinical product candidates.
Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.